Tesamorelin

What it is

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that was first approved by the FDA in 2010 under the brand name Egrifta. It contains the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification that extends its half-life and improves stability compared to natural GHRH.

The drug was specifically developed and approved for treating HIV-associated lipodystrophy, a condition where patients develop excess visceral (abdominal) fat as a side effect of antiretroviral therapy. However, its mechanism of action has made it valuable for broader applications in body composition optimization and age-related growth hormone decline.

Unlike direct growth hormone injection, tesamorelin works by stimulating the pituitary gland to release the body's own growth hormone in a more natural pulsatile pattern. This approach helps maintain the body's normal regulatory mechanisms while providing the benefits of increased growth hormone levels, including improved body composition, metabolism, and potentially cognitive function.

How it works

Tesamorelin binds to growth hormone-releasing hormone receptors (GHRH-R) in the anterior pituitary gland, triggering the release of endogenous growth hormone (GH) in discrete pulses that mimic the body's natural secretion pattern. This pulsatile release is crucial for maintaining proper GH signaling and avoiding desensitization of target tissues.

The released growth hormone then stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of growth hormone's effects on metabolism and tissue growth. IGF-1 promotes lipolysis (fat breakdown) particularly in visceral adipose tissue while supporting lean muscle mass preservation and protein synthesis.

Tesamorelin's trans-3-hexenoic acid modification protects it from enzymatic breakdown by dipeptidyl peptidase-4 (DPP-4), extending its biological activity compared to natural GHRH. This allows for once-daily dosing while maintaining effective GHRH receptor stimulation throughout the day.

The compound also appears to have direct effects on hypothalamic function beyond growth hormone release, potentially improving sleep quality, cognitive function, and metabolic regulation. Effects on growth hormone levels typically begin within 1-2 hours of injection and peak at 3-4 hours, with visceral fat reduction becoming apparent after 8-12 weeks of consistent use.

What the research shows

The most robust evidence for tesamorelin comes from the EGRIFTA trials, which enrolled 816 HIV patients with abdominal fat accumulation. After 26 weeks of treatment with 2 mg daily, patients experienced an average 15.2% reduction in visceral adipose tissue compared to 4.9% reduction with placebo, measured by CT scan (Falutz et al., The Lancet, 2010. PMID: 20638713).

Long-term follow-up data from the same trial showed sustained benefits at 52 weeks, with visceral fat reduction reaching 18.4% in the treatment group. Importantly, patients also showed significant improvements in IGF-1 levels (increasing by 181 ng/mL vs 11 ng/mL with placebo) and waist circumference reduction averaging 2.8 cm (Falutz et al., AIDS, 2011. PMID: 21399527).

Studies in aging populations without HIV have shown similar benefits. A 12-week trial in healthy adults over 65 found that tesamorelin 1 mg daily increased IGF-1 levels by 79% while reducing trunk fat by 6.7% compared to placebo. Participants also demonstrated improved cognitive performance on memory tests (Koutkia et al., Journal of Clinical Endocrinology & Metabolism, 2005. PMID: 15687342).

Research on muscle mass and strength shows more modest effects. While tesamorelin consistently increases lean body mass by 1-2 kg in clinical trials, functional strength improvements are variable. A study in growth hormone-deficient adults found significant increases in muscle mass but only modest improvements in exercise capacity (Johannsson et al., European Journal of Endocrinology, 2009. PMID: 19420190).

Typical protocol

The FDA-approved dosing for tesamorelin is 2 mg administered subcutaneously once daily, preferably in the evening to align with natural growth hormone secretion patterns. However, many practitioners start with 1 mg daily for the first 2-4 weeks to assess tolerance before increasing to the full therapeutic dose.

For off-label anti-aging or body composition applications, doses typically range from 1-2 mg daily. Higher doses do not appear to provide additional benefits and may increase side effects. Treatment duration varies, but most practitioners recommend minimum 12-week cycles to see meaningful changes in body composition.

Tesamorelin comes as a lyophilized powder that must be reconstituted with sterile water for injection. The standard vial contains 1 mg or 2 mg of tesamorelin acetate, reconstituted with 1-2 mL of sterile water to achieve appropriate concentration. Store reconstituted solution refrigerated and use within 3 days. Calculate exact reconstitution volumes using our peptide calculator.

Injection sites should be rotated between the abdomen, thigh, or upper arm to prevent lipodystrophy. Some practitioners recommend 5-day-on, 2-day-off cycles to prevent pituitary desensitization, though this approach isn't supported by clinical trial data. These protocols represent common clinical practices but should only be undertaken with proper medical supervision and monitoring of IGF-1 levels and glucose metabolism.

Side effects and risks

Tesamorelin demonstrates good tolerability in clinical trials, with most side effects being mild and transient. The most common adverse effects include injection site reactions (erythema, swelling, irritation) occurring in approximately 35% of users, though these typically resolve within the first few weeks of treatment.

Arthralgia (joint pain) and myalgia (muscle pain) affect roughly 15% of users, particularly during the initial weeks of treatment. These symptoms often subside as the body adapts to increased growth hormone levels, but may require dose reduction in some individuals.

Serious risks include potential glucose intolerance and insulin resistance, particularly in predisposed individuals. Clinical trials show increased fasting glucose levels in approximately 8% of users, with rare cases developing diabetes mellitus. Regular glucose monitoring is essential, especially in patients with metabolic risk factors.

Tesamorelin is contraindicated in patients with active malignancy due to growth hormone's potential to promote tumor growth. It should not be used during pregnancy or breastfeeding, and caution is warranted in patients with diabetes, hypothyroidism, or pituitary disorders. Drug interactions include potential enhancement of corticosteroid effects and possible interference with diabetes medications. Always consult an endocrinologist or physician experienced with growth hormone therapy before beginning treatment.

Related compounds